Business
Zealand Pharma turns to Generate Biomedicines' generative AI to design obesity drugs in an agreement valued at up to $1.2 billion
Zealand Pharma will pay Generate Biomedicines $30 million upfront to design multispecific protein drugs for obesity and metabolic disease with its generative AI platform, with milestones that could lift the deal to nearl…